Open AccessChidamide combined with cyclophosphamide, doxorubicin, vincristine and prednisone in previously untreated patients with peripheral T-cell lymphoma
Author(s) -
Lin Gui,
Junning Cao,
Dongmei Ji,
Huilai Zhang,
Qian Fan,
Jun Zhu,
Yuqin Song,
Shiyu Jiang,
Zhiqiang Ning,
Jia Yu,
Yuankai Shi
Publication year - 2021
Publication title -
chinese journal of cancer research/chinese journal of cancer research
Language(s) - English
Resource type - Journals
eISSN - 1993-0631
pISSN - 1000-9604
DOI - 10.21147/j.issn.1000-9604.2021.05.08
Subject(s) - medicine , febrile neutropenia , neutropenia , vincristine , tolerability , gastroenterology , leukopenia , cyclophosphamide , regimen , adverse effect , chop , pharmacology , surgery , chemotherapy
Chidamide is an oral histone deacetylase subtype-selective inhibitor approved for relapsed or refractory peripheral T-cell lymphoma (PTCL). This phase 1b study evaluated the safety, pharmacokinetics, and preliminary efficacy of chidamide in combination with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) for treatment-naïve PTCL patients.